Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study - Université de Nantes Accéder directement au contenu
Article Dans Une Revue Antimicrobial Agents and Chemotherapy Année : 2021

Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study

Vincent Dubee
Richard Danger
Odile Duvaux
  • Fonction : Auteur

Résumé

We assessed the pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in coronavirus disease 2019 (COVID-19)-related moderate pneumonia. The objective was to evaluate the optimal dose and safety of XAV-19 during this first administration to patients with COVID-19-related moderate pneumonia.

Dates et versions

hal-03378960 , version 1 (14-10-2021)

Identifiants

Citer

Benjamin Gaborit, Eric Dailly, Bernard Vanhove, Régis Josien, Karine Lacombe, et al.. Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study. Antimicrobial Agents and Chemotherapy, 2021, 65 (9), ⟨10.1128/AAC.01237-21⟩. ⟨hal-03378960⟩
24 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More